Do you know the NEW Registration Holder System for Medical Devices in China?Do you know the NEW post-market surveillance requirements in China?Do you know the latest clinical requirements in China?Do you have a plan in place for all the NEW changes in China? Join us for this webinar to have the answers to these questions.It will be an online presentation and Q&A given by Grace Fu Palma, CEO of ChinaMed Device.\u00a02pm – 3pm EST, December 12th, 2018Register NowIn Spring 2018, China\u2019s State Council unveiled a plan to reshuffle government ministries. Along with the reshuffling plan, the China Food and Drug Administration (CFDA) has now changed its name to the National Medical Product Administration (NMPA). The name change is just the tip of iceberg. The NMPA (CFDA) changes will offer both opportunities and challenges to many foreign companies targeting the Chinese market. ChinaMed is offering the online webinar to update you in the following areas:\u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Difference between USFDA and NMPA (CFDA)\u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Major NMPA (CFDA) Updates in 2018 (Hainan policy, new classification rules, legal agent, registration holder system, overseas clinical data etc.)\u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NMPA Registration Updates in the new era\u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NMPA Clinical Updates in the new era\u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Post-Market Compliance Updates in the new era Also, email us at info@ChinaMedDevice.com to receive our 2018 NMPA (CFDA) Almanac (soon to be published in January).\u00a0 It is a publication of the complete major 2018 NMPA (CFDA) listing of regulation, guidelines, technical standards, adverse events, etc. About ChinaMed Device, LLC\u00a0ChinaMed Device, LLC (www.ChinaMedDevice.com), a Boston headquartered company, provides regulatory and commercialization turnkey solutions for western medical device, IVD, CDx and combination products to enter China. Our NMPA (CFDA) regulatory services include: RA,\u00a0regulatory strategy,\u00a0regulatory submissions,\u00a0clinical evaluation reports (CER), clinical trials, QA, GMP and post-market compliance. Our commercialization services include: market assessment research, reimbursement, partnership\u00a0strategies, and distribution qualification. We are a NMPA (CFDA) certified legal agent with offices in Boston and Beijing enabling us to service our clients 24\/7.